Abstract Library

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#294 Chromogranin B is a Prognostic Marker in NETs

Introduction: Chromogranin B (CgB) co-localizes with Chromogranin A (CgA) in the secretory granules of neuroendocrine cells. Previous studies have investigated CgA, but not CgB, as a prognostic marker in NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Bech P, Ramachandran R, Martin N, Murphy K, Dhillo W,

Keywords: Chromogranin A, Chromogranin B, prognosis, neuroendocrine tumor, midgut,

#267 Plasma Somatostatin: Gastrin Ratio Improves the Diagnosis of Gastrinoma

Introduction: Fasting gastrin alone is inadequate for diagnosis of gastrinoma. Diagnosis requires confirmation of low gastric pH. Low gastric pH is associated with increased numbers of D (somatostatin) cells.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Ramachandran R, Bech P, Murphy K, Dhillo W, Marelli L,

Keywords: somatostatin, gastrin, ratio, gastrinoma, gastric pH, Cg A, atrophic gastritis ,